期刊
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
卷 86, 期 8, 页码 825-832出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/jnnp-2014-309098
关键词
-
资金
- Adamas Pharmaecuticals, Inc
- Allergan, Inc
- Auspex Pharmaceuticals, Inc [5D809]
- CHDI Foundation
- GE Healthcare
- Great Lakes NeuroTechnologies
- Huntington's Disease Society of America
- Huntington Study Group
- Ipsen Limited
- Kyowa Haako Kirin Pharma, Inc
- Lundbeck Inc
- Medtronic
- Merz Pharmaceuticals
- Michael J Fox Foundation for Parkinson Research
- National Institutes of Health
- National Parkinson Foundation
- Omeros Corporation [OMS824]
- Parkinson Study Group
- Pharma Two B
- Prothena Biosciences Inc [PRX002]
- Psyadon Pharmaceuticals (ecopipam), Inc
- St. Jude Medical
- Teva Pharmaceutical Industries Ltd
- UCB Inc
- University of Rochester
Catatonia is a complex neuropsychiatric syndrome characterised by a broad range of motor, speech and behavioural abnormalities. 'Waxy flexibility', 'posturing' and 'catalepsy' are among the well-recognised motor abnormalities seen in catatonia. However, there are many other motor abnormalities associated with catatonia. Recognition of the full spectrum of the phenomenology is critical for an accurate diagnosis. Although controlled trials are lacking benzodiazepines are considered first-line therapy and N-Methyl-oaspartate receptor antagonists also appears to be effective. Electroconvulsive therapy is used in those patients who are resistant to medical therapy. An underlying cause of the catatonia should be identified and treated to ensure early and complete resolution of symptoms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据